Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. ETF
  3. ABVX
ABVX logo

ABVX

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewTechnicalNews
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

ABVX News

Investment Outlook for Healthcare Stocks

4d agoFool

Biotech Companies Show Promising Clinical Progress

4d agoNASDAQ.COM

Abivax CEO: No Rush for Deals Ahead of Key Trial

6d agoseekingalpha

Abivax Reports €530.4M Cash Position for 2025

Mar 23 2026seekingalpha

Investment Opportunities in Abivax and Nektar Therapeutics

Mar 20 2026Fool

Abivax Viewed as a Potential Acquisition Target

Mar 20 2026NASDAQ.COM

Abivax Shares Rise After Denying AstraZeneca Acquisition Report

Mar 12 2026seekingalpha

AstraZeneca Poised to Acquire Abivax Amid Surge in Valuation

Mar 12 2026Benzinga

Petco Reports Strong Q4 Results, Shares Surge

Mar 12 2026Benzinga

Investing in Clinical-Stage Biotechs: Risks and Opportunities

Mar 10 2026Fool

Reasons Behind Abivax's 1000% Stock Surge

Feb 27 2026Fool

Abivax Presents New Findings on Obefazimod at ECCO Congress

Feb 21 2026NASDAQ.COM

Abivax Presents Obefazimod's First Evidence of Anti-Fibrotic Activity

Feb 21 2026Newsfilter

Eli Lilly's Decade of Market Dominance

Feb 11 2026Fool

Eli Lilly Sets High Bar, Competitors Follow Suit

Feb 11 2026NASDAQ.COM

Investment Comparison: AbbVie vs. Abivax

Jan 30 2026Fool